GSK: Japan approves new HIV two-drug pill
(CercleFinance.com) - GlaxoSmithKline has won approval to sell its once-daily, single-pill, two-drug regimen treatment of HIV in Japan, the world's second-biggest pharmaceutical market, the drugmaker said on Wednesday.
GSK's ViiV Healthcare has obtained approval of Dovato from the Japan Ministry of Health, Labour and Welfare for the treatment of HIV-1 infection, to be administered orally, it said.
The standard of care in Japan for people living with HIV has been with a three-drug regimen for many years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
GSK's ViiV Healthcare has obtained approval of Dovato from the Japan Ministry of Health, Labour and Welfare for the treatment of HIV-1 infection, to be administered orally, it said.
The standard of care in Japan for people living with HIV has been with a three-drug regimen for many years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.